MedTrace Logo

BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma

NCT02836639 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-07-19

No results posted yet for this study

Summary

Phase II study for safety and efficacy of BEB (Bendamustine, Etoposide, Busulfan) conditioning regimen for ASCT in non-Hodgkin's lymphoma

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

DRUG

Busulfan

Busulfan 0.8 mg/kg four times per day from day -7 to day -5

DRUG

Etoposide

Etoposide 400 mg/m2 from day -5 to day -4

DRUG

Bendamustine

Bendamustine 200 mg/m2 starting dose on day -3 and -2

Sponsors & Collaborators

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Hojin Shin · Pusan National Universty Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02836639 on ClinicalTrials.gov